Debt-to-equity of Taysha Gene Therapies, Inc. from 30 Jun 2021 to 30 Sep 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Taysha Gene Therapies, Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2021 to 30 Sep 2025.
Taysha Gene Therapies, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 60%, a 49% decline year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

Taysha Gene Therapies, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q3 2025	60%	-57%	-49%	30 Sep 2025
Q2 2025	75%	-208%	-73%	30 Jun 2025
Q1 2025	110%	-1207%	-92%	31 Mar 2025
Q4 2024	115%	+2317%		31 Dec 2024
Q3 2024	116%	+720%		30 Sep 2024
Q2 2024	283%	+1423%		30 Jun 2024
Q1 2024	1317%	-230%	-15%	31 Mar 2024
Q4 2023	-2202%	-2677%	-564%	31 Dec 2023
Q3 2023	-604%	-838%	-358%	30 Sep 2023
Q2 2023	-1140%	-1280%	-919%	30 Jun 2023
Q1 2023	1547%	+1464%	+1777%	31 Mar 2023
Q4 2022	475%	+429%	+940%	31 Dec 2022
Q3 2022	234%	+211%	+923%	30 Sep 2022
Q2 2022	139%	+129%	+1267%	30 Jun 2022
Q1 2022	82%			31 Mar 2022
Q4 2021	46%			31 Dec 2021
Q3 2021	23%			30 Sep 2021
Q2 2021	10%			30 Jun 2021

* An asterisk sign (*) next to the value indicates that the value is likely invalid.